French pharmaceutical group Sanofi said on Monday, September 28, it has finalized acquisition of United States biotech firm Principia Biopharma for $3.7 billion.
The operation, first announced in August, was aimed at boosting Sanofi’s research and development into autoimmune and allergic diseases.
Sanofi agreed to pay $100 per share in cash for Principia Biopharma, a company with which it has been cooperating since 2017.
That year, Sanofi secured an exclusive global license to develop and market Principia Biopharma BTK’168 drug for treating multiple sclerosis and other central nervous system illnesses.
“The Principia acquisition further strengthens our core areas of autoimmune and allergic diseases,” Sanofi chief executive Paul Hudson was quoted on Monday as saying.
Beyond diseases of the nervous system, Principia hopes to develop an entire portfolio of similar drugs that could target different organ systems in patients suffering from “immune-mediated” diseases, chief executive Martin Babler said last month. – Rappler.com
There are no comments yet. Add your comment to start the conversation.